NeurologyLive® Friday 5 — September 5, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Analyzing Eptinezumab’s Ability to Extend Interictal Periods and Reduce Migraine BurdenD

Amaal Starling, MD, FAHS, FAAN, associate professor of neurology at Mayo Clinic College of Medicine, shared data recently presented at AHS 2025 showing that eptinezumab extended the time between migraine attacks.

2:Putting Patients With Movement Disorders in the Driver’s Seat for Care: Cheryl Kyinn, PA-C

The physician assistant specializing in Parkinson disease talked about the shared decision-making process when discussing advanced therapies for movement disorder care with patients. [WATCH TIME: 3 minutes]

3: What Clinicians Should Know for Managing Hallucinations in Parkinson Disease: William Ondo, MD

The director of the Movement Disorders Clinic at Houston Methodist Hospital outlined a stepwise approach for identifying, managing, and treating hallucinations in patients with Parkinson disease. [WATCH TIME: 3 minutes]

4: NeuroVoices: Paul Ford, PhD, on Ethical Balance in Complex Clinical Research for Neurology

The director of the Neuroethics Program at Cleveland Clinic discussed the evolving role of ethics in neurological clinical trials, highlighting skill development, safeguards, and patient-centered decision-making.

5: Biomarker Advances and Challenges in Early Alzheimer Disease Detection: Sylvia Villeneuve, PhD

At AAIC 2025, the associate professor in the Department of Psychiatry at McGill University talked about the strengths and limitations of PET and blood biomarkers for Alzheimer disease. [WATCH TIME: 5 minutes]